Payment overview · 2025
General Payments
$27,222.40
260 reported records · 21 companies
Healthcare provider profile · identity verified
Eliscer Guzman, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · NEW YORK, NY · NPI 1679560833
Verified facts
What the public records show
CMS Open Payments records show Eliscer Guzman, MD received $27,222.40 in general payments during 2025 across 260 reported records.
AstraZeneca Pharmaceuticals LP accounted for 46.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Lokelma, Mounjaro, Nexletol, Ozempic, Rybelsus, Verquvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 1056 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 551 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 1326 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 737 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 1326 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 472 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 835 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 562 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 377 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 737 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $12,730.26 | 46.8% | 59 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8,839.25 | 32.5% | 31 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $1,621.12 | 6.0% | 7 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $538.19 | 2.0% | 10 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$480.77 | 1.8% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $351.47 | 1.3% | 16 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $313.32 | 1.1% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $309.17 | 1.1% | 15 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $295.65 | 1.1% | 20 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $270.11 | 1.0% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $249.25 | 0.9% | 13 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $242.02 | 0.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $219.27 | 0.8% | 22 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $182.52 | 0.7% | 10 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $156.17 | 0.6% | 8 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $121.16 | 0.5% | 5 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $111.55 | 0.4% | 4 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $77.90 | 0.3% | 3 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $68.09 | 0.2% | 3 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $24.70 | 0.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.46 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,600.00 | 13 |
| Food and Beverage | $6,622.40 | 247 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $11,769.91 | 17 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $10,039.25 | 32 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $730.61 | 34 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $538.19 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $351.47 | 16 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $343.16 | 29 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $295.65 | 20 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $290.35 | 14 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $270.11 | 11 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $249.25 | 13 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $242.02 | 5 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $214.01 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $189.83 | 20 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $182.52 | 10 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $166.49 | 3 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $160.88 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $156.17 | 8 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $153.40 | 1 | 2025 |
Source payment records
|
|||||
| MCOT Normalized: mcot |
Device | Philips North America LLC | $121.16 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $121.12 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $121.12 | 5 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $111.55 | 4 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $77.90 | 3 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $68.09 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $65.09 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.34 | 2 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 737 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 1056 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 1326 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 551 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 172 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 202 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 562 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 377 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
1056 | 297 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
172 | 84 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
551 | 143 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
1326 | 358 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
91 | 32 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
737 | 183 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
221 | 63 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
1326 | 358 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
202 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
472 | 109 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
835 | 190 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
562 | 119 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
377 | 97 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
737 | 183 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 3195 | 1151 |
| Metoprolol Succinate | Metoprolol Succinate | 1483 | 507 |
| Jardiance | Empagliflozin | 1326 | 358 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1138 | 409 |
| Farxiga | Dapagliflozin Propanediol | 1056 | 297 |
| Ezetimibe | Ezetimibe | 991 | 330 |
| Clopidogrel | Clopidogrel Bisulfate | 854 | 274 |
| Entresto | Sacubitril/Valsartan | 835 | 190 |
| Amlodipine Besylate | Amlodipine Besylate | 831 | 345 |
| Losartan Potassium | Losartan Potassium | 790 | 306 |
| Eliquis | Apixaban | 737 | 183 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 730 | 226 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 612 | 208 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 597 | 198 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 570 | 202 |
| Lisinopril | Lisinopril | 562 | 226 |
| Ozempic | Semaglutide | 562 | 119 |
| Kerendia | Finerenone | 551 | 143 |
| Labetalol Hcl | Labetalol Hcl | 503 | 152 |
| Metformin Hcl | Metformin Hcl | 489 | 218 |
| Torsemide | Torsemide | 484 | 147 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 472 | 174 |
| Trulicity | Dulaglutide | 472 | 109 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 463 | 173 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 397 | 175 |
| Xarelto | Rivaroxaban | 392 | 104 |
| Rybelsus | Semaglutide | 377 | 97 |
| Spironolactone | Spironolactone | 356 | 108 |
| Furosemide | Furosemide | 342 | 116 |
| Simvastatin | Simvastatin | 341 | 128 |
| Januvia | Sitagliptin Phosphate | 328 | 108 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 322 | 112 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 292 | 96 |
| Metformin Hcl Er | Metformin Hcl | 279 | 98 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 274 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 250 | 102 |
| Vascepa | Icosapent Ethyl | 250 | 71 |
| Clonidine | Clonidine | 248 | 47 |
| Nitroglycerin | Nitroglycerin | 247 | 81 |
| Carvedilol | Carvedilol | 245 | 87 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 221 | 63 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 210 | 73 |
| Mounjaro | Tirzepatide | 202 | 46 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 201 | 64 |
| Benazepril Hcl | Benazepril Hcl | 184 | 62 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 178 | 70 |
| Repatha Sureclick | Evolocumab | 175 | 40 |
| Lokelma | Sodium Zirconium Cyclosilicate | 172 | 84 |
| Omeprazole | Omeprazole | 157 | 56 |
| Pioglitazone Hcl | Pioglitazone Hcl | 153 | 69 |
| Nebivolol Hcl | Nebivolol Hcl | 152 | 50 |
| Hydralazine Hcl | Hydralazine Hcl | 146 | 54 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 141 | 61 |
| Valsartan | Valsartan | 138 | 53 |
| Chlorthalidone | Chlorthalidone | 127 | 49 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 123 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 49 |
| Meclizine Hcl | Meclizine Hcl | 116 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 47 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 93 | 30 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 93 | 27 |
| Synjardy | Empagliflozin/Metformin Hcl | 91 | 32 |
| Nifedipine Er | Nifedipine | 87 | 41 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 83 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 82 | 30 |
| Verapamil Er | Verapamil Hcl | 75 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 69 | 32 |
| Candesartan Cilexetil | Candesartan Cilexetil | 66 | 17 |
| Glipizide | Glipizide | 55 | 25 |
| Clonidine Hcl | Clonidine Hcl | 54 | 17 |
| Ranolazine Er | Ranolazine | 52 | 15 |
| Atenolol | Atenolol | 51 | 23 |
| Irbesartan | Irbesartan | 50 | 18 |
| Linzess | Linaclotide | 50 | 18 |
| Colchicine | Colchicine | 47 | 11 |
| Repatha Syringe | Evolocumab | 45 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 42 | 16 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 41 | 14 |
| Eplerenone | Eplerenone | 41 | 14 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Brilinta | Ticagrelor | 35 | 11 |
| Glipizide Er | Glipizide | 34 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 33 | 12 |
| Fenofibrate | Fenofibrate,micronized | 31 | 13 |
| Enalapril Maleate | Enalapril Maleate | 30 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 29 | 13 |
| Verquvo | Vericiguat | 29 | suppressed |
| Praluent Pen | Alirocumab | 25 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 25 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | 14 |
| Telmisartan | Telmisartan | 24 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 22 | suppressed |
| Gabapentin | Gabapentin | 22 | 11 |
| Tradjenta | Linagliptin | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 20 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 14 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Nexletol | Bempedoic Acid | 13 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $27,222.40 · 260 records | AstraZeneca Pharmaceuticals LP | ABRE, Attruby, CAMZYOS, CAPVAXIVE, ELIQUIS, FARXIGA, FFRct, FREESTYLE LIBRE 3, FUROSCIX, HAWKONE, IN.PACT ADMIRAL, JARDIANCE, Kerendia, Korlym, LEQVIO, LOKELMA, MCOT, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, RECORLEV, REPATHA, REZDIFFRA, Rybelsus, VERQUVO, Veltassa, WAINUA, Wegovy, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error